RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q2 2025
Top Holdings73 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MADRIGAL PHARMACEUTICALS INC | 2M | $603.4M | 8.6% | $265.36 | +13.33% | 9 qtrssince 2023-Q2 | Unchanged 0 |
NATERA INC | 2.6M | $438.2M | 6.2% | $42.13 | +298.68% | 24 qtrssince 2019-Q3 | Increased 60 |
PTC THERAPEUTICS INC | 7.7M | $378.3M | 5.4% | $43.73 | +13.97% | 26 qtrssince 2019-Q1 | Increased 63 |
ARGENX SE - ADR | 673,497 | $371.2M | 5.3% | $355.08 | +57.75% | 26 qtrssince 2019-Q1 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.8M | $318.1M | 4.5% | $24.36 | +128.66% | 24 qtrssince 2019-Q3 | Increased 57 |
INSMED INC | 3.1M | $310.4M | 4.4% | $45.51 | +118.62% | 9 qtrssince 2023-Q2 | Increased 58 |
AKERO THERAPEUTICS INC | 5.5M | $292.3M | 4.2% | $26.19 | +114.55% | 7 qtrssince 2023-Q4 | Decreased 0 |
VERONA PHARMA PLC | 3.1M | $288.6M | 4.1% | — | — | 3 qtrssince 2024-Q4 | Increased 61 |
| 9.6M | $273.2M | 3.9% | $26.45 | +9.75% | 21 qtrssince 2020-Q2 | Increased 62 | |
STRYKER CORP | 590,517 | $233.6M | 3.3% | $356.27 | +9.70% | 4 qtrssince 2024-Q3 | Increased 56 |
PENUMBRA INC | 863,553 | $221.6M | 3.2% | $249.62 | +2.73% | 16 qtrssince 2021-Q3 | Increased 56 |
MERUS N V | 4M | $210.4M | 3.0% | $34.06 | +55.59% | 9 qtrssince 2023-Q2 | Decreased 0 |
ACADIA Pharmaceuticals Inc. | 9M | $194M | 2.8% | $18.54 | +19.31% | 13 qtrssince 2022-Q2 | Increased 55 |
ZAI LAB LTD | 5.5M | $193.6M | 2.8% | $31.28 | +11.06% | 3 qtrssince 2024-Q4 | Increased 79 |
AXSOME THERAPEUTICS INC | 1.5M | $158.3M | 2.3% | $62.01 | +66.67% | 26 qtrssince 2019-Q1 | Decreased 0 |
RadNet, Inc. | 2.7M | $153.1M | 2.2% | $48.58 | +17.57% | 7 qtrssince 2023-Q4 | Increased 60 |
IMMUNOCORE HLDGS PLC | 4.9M | $152.8M | 2.2% | $43.05 | -27.71% | 18 qtrssince 2021-Q1 | Unchanged 0 |
ALKERMES PLC | 4.7M | $134M | 1.9% | $27.26 | +5.69% | 8 qtrssince 2023-Q3 | Decreased 0 |
NEUROCRINE BIOSCIENCES INC | 1.1M | $133.5M | 1.9% | $125.42 | 0.00% | 1 qtr | New 69 |
TARSUS PHARMACEUTICALS INC | 3.1M | $126.1M | 1.8% | $33.23 | +21.42% | 19 qtrssince 2020-Q4 | Decreased 0 |
RTW INVESTMENTS, LP manages $7B across 73 positions as of Q2 2025. Top holdings: MDGL (8.6%), NTRA (6.2%), PTCT (5.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2.5/5.0.
Active quarter - 10 new positions, 5 exits, 26 increased. Top move: ZLAB (INCREASED, conviction 79). Portfolio: $7.0B across 73 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer